Stifel Nicolaus analyst Derek Archila reiterated a Hold rating on Selecta Biosciences (SELB) today and set a price target of $2.00. The company’s shares closed last Thursday at $3.11.
According to TipRanks.com, Archila is a 4-star analyst with an average return of 10.7% and a 49.8% success rate. Archila covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Madrigal Pharmaceuticals, and Phasebio Pharmaceuticals.
Currently, the analyst consensus on Selecta Biosciences is a Moderate Buy with an average price target of $5.40, implying a 69.3% upside from current levels. In a report released today, William Blair also downgraded the stock to Hold.
See today’s analyst top recommended stocks >>
Based on Selecta Biosciences’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $24.08 million. In comparison, last year the company earned revenue of $13K and had a GAAP net loss of $16.39 million.
Based on the recent corporate insider activity of 16 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SELB in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Selecta Biosciences, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. it produces the Synthetic Vaccine Particles (SVP) platform for immune tolerance and immune stimulation. The firm proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. The company was founded by Omid C. Farokhzad, Robert S. Langer Jr., and Ulrich von Andrian in 2007 and is headquartered in Watertown, MA.
